Most Recent Articles by Diana Ernst, RPh
According to a Phase 3b open-label study, Ocrevus may interfere with the effectiveness of non-live vaccines.
The FDA has issued a safety communication regarding the risks associated with implanted pumps for intrathecal administration of pain medications.
The authors found that the compounds known as phenylindanes inhibited the aggregation of the amyloidgenic proteins beta-amyloid and tau.
The Food and Drug Administration (FDA) approved the treatment in June 2018, making it the first prescription pharmaceutical formulation of highly-purified, plant-derived cannabidiol, as well as the first treatment indicated for patients with Dravet syndrome.
To investigate the link between organic food consumption and cancer risk, study authors conducted a population-based prospective cohort study among French adults.
More Articles by Diana Ernst, RPh
Neurology Advisor Articles
- Multiple System Atrophy: A Common Form of Atypical Parkinsonism
- Migraine Treatment in the ED: Overcoming Our Penchant for Opioids
- Erenumab as a Therapy for Hard to Treat Episodic Migraine
- Nusinersen May Be Effective for Short-Term Motor Function Improvements in Spinal Muscular Atrophy
- Reduced Survival for Patients With Idiopathic Parkinsonism
- New Diagnostic Criteria for Neurosarcoidosis: What You Need to Know
- Guideline for Diagnosis and Treatment of Idiopathic Intracranial Hypertension
- Guidelines on the Use of OnabotulinumtoxinA for Chronic Migraine
- Ivy League Rule Change Linked to Fewer Concussions During NCAA Football Games
- Biomarkers of Alzheimer Disease Observed in Down Syndrome
- Approaches for Better Diagnosis of Pediatric Multiple Sclerosis
- Short Segment Sensory Nerve Stimulation Offers Potential Diagnostic Value for Ulnar Neuropathy
- Incidence of Guillain-Barré Syndrome Linked With Recent Bone, Digestive Organ Surgery
- Online Tool Helps Patients With Advance Care Planning
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems